Under the partnership, Mayo Clinic’s multimodal datasets, laboratories and clinical expertise will combine with Nucleai’s AI platform to develop new offerings for biomarker discovery and validation, end-to-end spatial biology testing and algorithm deployment for clinical trials and diagnostic use, according to a June 4 press release from Nucleai.
The aim is for both entities to create new digital pathology solutions, technologies and services to support drug development and clinical practice.
